You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Certaines de ces informations ou toutes, dans certains cas, n’apparaissent qu’en Anglais. Vous pouvez demander la version française

Médicaments

La bibliothèque de médicaments donne accès à des renseignements sur plus de 100 médicaments anticancéreux commercialisés au Canada.

Trouvez plus d’information sur la sécurité  dans le document patient supplémentaire Comment prendre vos médicaments oraux contre le cancer de manière sécuritaire.

Displaying Drugs List

171 Items
Other Name(s): Zytiga® (Janssen)
Funding:
Exceptional Access Program
  • abiraterone - Metastatic castrate-resistant prostate cancer, with specific criteria
Sep 2019
Other Name(s): Giotrif®
Funding:
Exceptional Access Program
  • AFAtinib - For first-line monotherapy treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC), according to specific criteria
Jun 2019
Other Name(s): Zaltrap®
Jun 2019
Other Name(s): Proleukin® (interleukin-2)
Funding:
New Drug Funding Program
  • Aldesleukin (interleukin-2) - In-Transit Metastases from Melanoma
Jun 2019
Other Name(s): Alecensaro™
Funding:
Exceptional Access Program
  • Treatment of non-small cell lung cancer according to clinical criteria
Jun 2019
Other Name(s): MabCampath®
Sep 2019
Other Name(s): AMSA P D® (Erfa)
Sep 2011
Other Name(s): Agrylin® (Shire Pharma)
Jul 2017
Other Name(s): Arimidex® (multiple brands available)
Funding:
ODB Limited Use
  • anastrozole - For the treatment of metastatic breast cancer in hormone receptor positive post-menopausal women
  • anastrozole - An alternative to tamoxifen for the adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer
Apr 2016
Other Name(s): Erleada® ()
Nov 2018
Other Name(s): Trisenox® (Lundbeck)
Funding:
New Drug Funding Program
  • Arsenic Trioxide - First Line Consolidation of Acute Promyelocytic Leukemia (APL)
  • Arsenic Trioxide - First Line Induction of Acute Promyelocytic Leukemia (APL)
  • Arsenic Trioxide - Relapsed_Refractory Induction of Acute Promyelocytic Leukemia (APL)
  • Arsenic Trioxide - Relapsed_Refractory Consolidation of Acute Promyelocytic Leukemia (APL)
Apr 2016
Aug 2016